Lauruslabs

'Expect The CDMO Business To Witness Recovery In H2': Laurus Lab's Founder & CEO On Talking Point

NDTV Profit Markets

Laurus Lab - 2 Minute Analysis #lauruslab

Basant Maheshwari - The Equity Desk

A glimpse of Laurus Labs FDF and API, Integrated Unit - No 2 at Atchutapuram, APSEZ, Visakhapatnam

Significant Investments In Capacity Expansion, R&D Have Impacted Current Margin Figure: Laurus Labs

Laurus Lab Q2 Result: CDMO Growth Sentiment, Plan For Expansion & FY25 Guidance| Satyanarayana Chava

The development of quality-assured generic medicines explained by Laurus Labs

MedicinesPatentPool

Laurus Labs Q4 Results: CEO Satyanarayana Chava Dissects Numbers | Talking Point | NDTV Profit

Laurus Labs Ltd Q2 FY2024-25 Earnings Conference Call

AlphaStreet India

Laurus Labs, Piramal Pharma Etc In Focus After US House Of Representatives Passes The Biosecure Act

Laurus Labs Founder And CEO Dr. Satyanarayana Chava Exclusive Interview | N Business

Laurus Labs Will Rally Like Crazy Between 2024-2028

Laurus Labs Earnings: In-Line Show In Q2, CDMO Segment Sees Growth Aided By Resource Allocation

Laurus Labs Q1 Misses Estimates, Company Expects A Pick Up In Second Half Of FY25

Laurus Labs Is Very Near To Give Multibagger Returns In Next 2-3yrs

Dr Chava Satyanarayana Special Interview on Laurus Labs IPO

Laurus Labs Stock Analysis | An Emerging Moat?

SOIC

'Expect Uptick In CDMO Revenue In H2 FY25': Laurus lab Founder & CEO

Laurus Labs Earnings Call for Q1FY25

Laurus Labs Founder And CEO Dr.Chava Satyanarayana Exclusive Interview | Sakshi TV Business

Sakshi TV Business

Laurus Labs DR Satyanarayana Chava Interview | Promo | | N Business